By Iain Gilbert
Date: Friday 13 Feb 2026
(Sharecast News) - Shore Capital downgraded drugmaker AstraZeneca from 'buy' to 'hold' on Friday, stating the drugmaker's near‑term earnings outlook looked less favourable despite what it called "exceptional" R&D delivery.
| SkinBioTherapeutics CEO resigns | 13-Feb-2026 | ShareCast |
| Oxford Biomedica extends 'put up or shut up' dea... | 11-Feb-2026 | ShareCast |
| China's CDE accepts GSK's regulatory filing for ... | 10-Feb-2026 | ShareCast |
| Annual sales, profits jump at AstraZeneca | 10-Feb-2026 | ShareCast |
| JP Morgan raises target price on GSK | 09-Feb-2026 | ShareCast |
| Result of AGM | 13-Feb-2026 | 16:31 | RNS |
| Form 8.3 - Oxford Biomedica plc | 13-Feb-2026 | 15:20 | RNS |
| Further CEO Share Purchase | 13-Feb-2026 | 14:30 | RNS |
| Director/PDMR Shareholding | 13-Feb-2026 | 08:01 | RNS |
| Form 8.5 (EPT/RI) - Oxford Biomedica plc | 13-Feb-2026 | 07:36 | RNS |
| Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
| Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
| Investment Column:BTG | 06-Oct-2011 | The Independent |
| Investment Column:Genus | 09-Sep-2011 | The Independent |
| Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
| Price | 28,627.08 |
| Closing Price Change | 355.28 |
| % Change | 1.26 % |
| 13-Feb-26 Close | 28,627.08 |
You are here: research